bims-carter Biomed News
on CAR-T Therapies
Issue of 2026–07–26
47 papers selected by
Luca Bolliger, lxBio



  1. PLoS Med. 2026 Jul;23(7): e1005179
      Chimeric antigen receptor (CAR)-expressing cells bear a great potential for the treatment of autoimmune diseases. While numerous challenges persist, recent technological developments have demonstrated the potential for CAR cells to reset dysfunctional immune systems and transform care for patients with autoimmune disease.
    DOI:  https://doi.org/10.1371/journal.pmed.1005179
  2. Front Immunol. 2026 ;17 1893076
      Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment of hematologic malignancies, yet its efficacy in solid tumors and durability across broader application remain limited. A central challenge lies in how CAR signaling is initiated, amplified, and regulated over time. Unlike the native T cell receptor (TCR), CARs are synthetic, modular receptors whose signaling output is dictated by the composition and spatial organization of their extracellular, transmembrane, and intracellular domains. Emerging evidence suggests that CAR signaling requirements are not static: insufficient signaling at early time points can impair activation and tumor clearance, whereas excessive or prolonged signaling promotes exhaustion, toxicity, and loss of persistence. More recent CAR designs therefore emphasize fine-tuned signaling, embracing a "less-is-more" paradigm to balance potency with durability. In this review, we summarized recent advances in CAR signaling biology, focusing on temporal signaling thresholds, modular design principles, and emerging strategies to precisely control signal strength and quality. Finally, we discuss how high-throughput screening, computational modeling, and machine learning approaches may enable disease-specific, personalized CAR designs in the future.
    Keywords:  CAR-T; T cell signaling; artificial intelligence (AI); cancer immunotherapy; machine learning
    DOI:  https://doi.org/10.3389/fimmu.2026.1893076
  3. Cancer Cell Int. 2026 Jul 20.
      The approval of lifileucel in 2024 marked an important milestone in oncology as the first cellular therapy authorized for a solid tumor. This milestone stands in sharp contrast to the success of CAR-T cells in hematologic malignancies, where six products have been licensed, and highlights the central challenge that solid tumors remain largely unconquered. At the mechanistic core lies a three-stage framework describing the major barriers encountered by therapeutic T cells in solid tumors, a series of escalating barriers that any therapeutic T cell must overcome to achieve durable tumor control: (1) Access: overcoming stromal and vascular barriers that restrict T-cell infiltration into tumors, (2) Recognition: identifying malignant cells in the setting of antigen heterogeneity and immune evasion, and (3) Persistence: maintaining T-cell function within the immunosuppressive tumor microenvironment. Historically, CAR-T and TIL therapies were viewed in competition, each occupying distinct niches. The field is increasingly adopting a convergent paradigm in which both platforms address a common challenge: overcoming the biological barriers that limit durable responses in solid tumors through complementary engineering and biological strategies. We review the biological obstacles, emerging convergence strategies, and translational frameworks including biomarker-guided patient selection that define this new area. Therapeutic selection may increasingly be guided by a tumor's dominant biological barriers rather than by platform classification alone.
    DOI:  https://doi.org/10.1186/s12935-026-04425-w
  4. Biochem Pharmacol. 2026 Jul 20. pii: S0006-2952(26)00615-5. [Epub ahead of print]253(Pt 1): 118276
      Immune checkpoint inhibitors have transformed cancer treatment; however, resistance, on-target toxicity, and limited efficacy in autoimmune disorders have motivated next-generation immunotherapies. T cell engagers (TCEs) redirect cytotoxic T cells to kill pathogenic cells independently of MHC restriction, whereas antibody-drug conjugates (ADCs) deliver potent payloads directly into target cells via receptor-mediated internalization. This review synthesizes preclinical and clinical data on TCEs and ADCs in oncology and immune-mediated inflammatory disorders (IMIDs). The CD47/SIRPα innate immune checkpoint is briefly examined as a case study in next-generation immunopharmacology, with agents like evorpacept and BYON4228 showing encouraging objective response rates (50% ORR) in non-hodgkin lymphoma when combined with rituximab, with next-generation designs reducing hematologic toxicity. Recent compassionate use findings in autoimmunity demonstrate that CD19 × CD3 TCE (blinatumomab) and (B-cell maturation antigen) BCMA × CD3 TCE (teclistamab) elicit rapid clinical improvement in refractory antisynthetase syndrome and systemic sclerosis, accompanied by cytokine release syndrome (CRS) (grade 3 in 40% and 100% of patients, respectively) and no neurotoxicity. In engineered TCEs with attenuated CD3 affinity, grade 1-2 CRS occurs in < 20% of patients. Beyond cell-depleting strategies, bispecific antibodies targeting OX40L/TNFα and anti-TL1A antibodies are advancing in hidradenitis suppurativa and rheumatic diseases. Conversely, ADC strategies have yielded mixed results; an anti-TNF-glucocorticoid receptor modulator ADC failed to outperform adalimumab in a phase 2b trial. Safety profiles differ: TCEs predominantly cause cytokine release syndrome, whereas ADCs pose off-target payload toxicity risks. Emerging dual-targeting TCEs, half-life-extended formats, and rational combinations illustrate key immunopharmacological principles that may broaden the therapeutic landscape for cancer and autoimmune diseases.
    Keywords:  Antibody-drug conjugate; Autoimmune disease; Bispecific antibody; CAR-T; CD47/SIRPα; Cancer immunotherapy; Cytokine release syndrome; T cell engager
    DOI:  https://doi.org/10.1016/j.bcp.2026.118276
  5. Front Immunol. 2026 ;17 1870668
      Chimeric Antigen Receptor-Natural Killer Cell (CAR-NK) is a promising next-generation immunotherapy. Persistence of CAR-NK cell therapy is considered a key hurdle limiting its full therapeutic potential. This review highlighted the causes of poor CAR-NK persistence and summarized strategies developed to improve CAR-NK persistence in both hematologic malignancies and solid tumors. These strategies included cytokine and cytokine signaling mediated strategies; optimization of NK cell source and CAR design; intrinsic and extrinsic checkpoint disruption and metabolic reprogramming; and lymphodepletion, alloevasion and fratricide evasion strategies. Multiple strategies that aim at improving in vivo persistence should prove useful in enhancing therapeutic efficacy of CAR-NK.
    Keywords:  CAR; NK; genetic engineering; persistence; tumor immunotherapy
    DOI:  https://doi.org/10.3389/fimmu.2026.1870668
  6. BioDrugs. 2026 Jul 21.
      Advanced therapy medicinal products (ATMPs) promise transformative clinical potential, but their use remains limited by complex manufacturing, high prices, and fragmented market access. To explore the existing and potential regulatory pathways to increase access to ATMPs, we conducted a product-level analysis of ATMPs and biologic medicines submitted to the European Medicines Agency up to May 2026, and a review of regulatory pathways and policy frameworks. While certain scientific principles from biologic and biosimilar regulation, such as totality of evidence, fit-for-purpose data, and tailored approaches are transferable, the biosimilar pathway may not be suitable for certain ATMPs. Other approaches, including bio-hybrid applications or prior knowledge-based dossiers, may be better suited to support competitive entry and second-wave innovation. Tailored follow-on pathways, open and well governed platform technologies, and supportive industrial and data sharing policies, are key to facilitate the translation of the scientific promise of ATMPs into sustainable and equitable patient access.
    DOI:  https://doi.org/10.1007/s40259-026-00797-7
  7. Cancer Discov. 2026 Jul 21. OF1
      China has approved the first CAR T-cell therapy that targets solid tumors, satricabtagene autoleucel (satri-cel), for patients with claudin 18.2-positive, HER2-negative gastric or gastro-esophageal junction cancer. The approval stems from a phase II trial that found the cells increased progression-free survival and overall survival. Scientists are excited about the decision but caution that more research is necessary to improve the effectiveness of CAR T cells against solid tumors.
    DOI:  https://doi.org/10.1158/2159-8290.CD-NW2026-0078
  8. Med. 2026 Jul 22. pii: S2666-6340(26)00229-1. [Epub ahead of print] 101226
       BACKGROUND: B cell-targeting chimeric antigen receptor (CAR) T cell therapy has shown efficacy in autoimmune diseases but is limited by toxicity, complex manufacturing, and high cost. Umbilical cord blood (UCB)-derived CAR-natural killer (CAR-NK) cells offer an alternative "off-the-shelf" platform with a potentially superior safety profile. We developed a UCB-derived CD19-targeting CAR-NK product incorporating the 4-1BB costimulatory domain (CD19-BBz) and evaluated its safety and efficacy in refractory systemic lupus erythematosus (SLE). This study was registered at ClinicalTrials.gov (ClinicalTrials.gov: NCT06421701).
    METHODS: In this phase 1, open-label, dose-escalation study, five patients with refractory SLE received lymphodepletion chemotherapy followed by infusion of allogeneic CD19-BBz CAR-NK cells. Dosing followed a step-up regimen, with the highest total dose being 1.35 × 109 cells-2.2- to 3.3-fold lower than the highest doses previously reported for CAR-NK therapy in SLE.
    FINDINGS: Treatment was exceptionally well tolerated. No grade ≥2 cytokine release syndrome and no neurotoxicity or graft-versus-host disease occurred. All patients achieved profound B cell depletion, with nadir circulating B cell levels ranging from 0.16 to 1.44 cells/μL. All patients achieved an SLE Responder Index-4 response by month 1. The lupus low disease activity state was attained in all patients by month 9, and 80% (4/5) met the definition of remission in SLE by the last follow-up (median, 12 months). Reconstituted B cells displayed a sustained naive-dominant repertoire.
    CONCLUSIONS: Low-dose UCB-derived CD19-BBz CAR-NK cell therapy demonstrated an excellent safety profile and induced robust, durable clinical responses in refractory SLE.
    FUNDING: This study was supported by the Noncommunicable Chronic Diseases-National Science and Technology Major Project (2023ZD0501300).
    Keywords:  CAR-NK; immune reset; systemic lupus erythematosus; translation to patients
    DOI:  https://doi.org/10.1016/j.medj.2026.101226
  9. Immunology. 2026 Jul 22.
      Chimeric antigen receptor T (CAR-T) cell therapy has transformed the treatment of relapsed or refractory haematologic malignancies, but immune effector cell-associated neurotoxicity syndrome (ICANS) remains a major and potentially life-threatening complication. Although most patients with ICANS improve after standard corticosteroid therapy, a subset shows insufficient improvement or neurological deterioration after corticosteroid initiation, a clinical scenario often described as corticosteroid-refractory or steroid-refractory ICANS. ICANS develops through a cascade initiated by CAR-T cell expansion and systemic cytokine release, followed by endothelial activation, blood-brain barrier disruption, glial-driven neuroinflammation, and neuronal injury. This process may be further amplified by on-target off-tumour effects and extracellular vesicles released from CAR-T cells. ICANS risk is influenced by CAR construct design, target antigen, and disease context. Several tools may contribute to multimodal risk assessment, including the Immune Effector Cell-Associated Encephalopathy (ICE) score, EASIX/m-EASIX, ICANS-PSS, CART-NS, cytokine profiles, neurofilament light chain, electroencephalography, and imaging, although their predictive value requires further validation. This review summarises the cytokine-mediated mechanisms, product-specific risk patterns, and early recognition strategies of ICANS after CAR-T cell therapy. It also critically appraises emerging investigational approaches for corticosteroid-refractory ICANS, including cytokine-directed interventions, endothelial-stabilising strategies, tyrosine kinase inhibition, CAR-T cell depletion, intrathecal therapy, and engineered suicide gene systems.
    Keywords:  CAR‐T cell therapy; blood–brain barrier; corticosteroid‐refractory; cytokines; immune effector cell‐associated neurotoxicity syndrome
    DOI:  https://doi.org/10.1111/imm.70171
  10. Mol Ther Adv. 2026 Sep 10. 34(3): 201802
      Immunotherapy stands as one of the most promising approaches in cancer treatment, with engineered T cell therapies, particularly chimeric antigen receptor T cell (CAR-T), leading the charge. However, relapse in some patients post-treatment suggests that research in this field remains incomplete. Tumor heterogeneity and the complexities of the immune microenvironment hinder a comprehensive understanding of the changes engineered T cells undergo once introduced into the human body. Single-cell lineage tracing (SCLT) technology facilitates the investigation of cellular development by monitoring the fate and differentiation of individual cells and their descendants within an organism. Employing methodologies such as CRISPR-based labeling and mitochondrial DNA tracking, SCLT allows for dynamic analysis of T cell clonal evolution, exhaustion mechanisms, and memory cell generation. This approach offers single-cell resolution data that contribute to resolving pertinent clinical challenges. This article provides a comprehensive review of recent developments and characteristics of the SCLT multi-omics approach. It elucidates the manner in which SCLT addresses the conventional constraints associated with spatiotemporal resolution and introduces a novel methodology for generating DNA barcodes to monitor CAR-T cells via CRISPR technology. These contributions offer valuable perspectives for the enhancement of cell therapy strategies.
    Keywords:  CAR-T; CRISPR; immunotherapy; lineage tracing; scRNA-seq
    DOI:  https://doi.org/10.1016/j.omta.2026.201802
  11. Hum Vaccin Immunother. 2026 Dec;22(1): 2690723
      This study aims to analyze the global research patterns and emerging trends in CAR-T cell therapy for ALL through a bibliometric analysis. Publications were retrieved from the Web of Science Core Collection database. The bibliometric analysis utilized VOSviewer, CiteSpace, and the R package "bibliometrix" to visualize collaborations, keyword co-occurrences, and emerging research trends. A total of 844 articles from 253 journals by 6,459 authors across 44 countries were analyzed, showing an annual growth rate of 40.08%. The USA (372 articles, 38,065 citations) and China (275 articles, 5,636 citations) dominated research output. The University of Pennsylvania (353 articles), Memorial Sloan Kettering Cancer Center (170), and Children's Hospital of Philadelphia (131) were the most productive institutions, while Blood (41 articles) published the most articles. Stephan A. Grupp (38 articles, H-index = 30), Carl H. June (26 articles, H-index = 24), and Shannon L. Maude (25 articles, H-index = 20) were the most influential authors. Keyword analysis revealed five research clusters, including basic mechanisms, CAR design, population treatment integration, clinical outcomes, and toxicity management. Burst keyword analysis showed the evolution from basic science (2010-2013) to clinical translation (2014-2016), toxicity management (2017-2019), and recently to long-term outcomes and risk assessment (2020-2024), with "term follow-up" and "risk" as the only keywords with active bursts in 2024. This bibliometric analysis reveals that research on CAR-T therapy for ALL has progressed from foundational concepts to clinical implementation and now focuses on optimizing long-term outcomes and patient selection. Future research should prioritize biomarker development, next-generation CAR designs, and combination strategies to overcome persistence, toxicity, and resistance limitations in ALL treatment.
    Keywords:  Chimeric antigen receptor T-cell immunotherapy; CiteSpace; VOSviewer; bibliometric analysis; cluster analysis; lymphoblastic leukemia
    DOI:  https://doi.org/10.1080/21645515.2026.2690723
  12. Cancer Immunol Res. 2026 Jul 22.
      Chimeric antigen receptor (CAR)-T cell therapy has become a promising clinical approach against hematological malignancies, but patients receiving CAR-T cell therapy still presented inconsistent clinical outcomes and are complicated by incomplete tumor eradication. The gut microbiome has shown strong correlation with the therapeutic outcomes of CAR-T cell therapy. However, the underlying mechanism of how gut microbiota affect CAR-T cell therapeutic potency remained undetermined. In this study, we established a syngeneic CD19+ murine lymphoma model which allows for the evaluation of both endogenous immune cells and gut microbiota following CD19-CD28ζ CAR-T therapy. Using single-cell transcriptomic analyses, we report that CAR-T cell infusion led to the activation of peripheral and gut-infiltrating endogenous CD8+ T cells towards an effector-like phenotype. In parallel, 16S RNA sequencing revealed substantial alterations of gut microbiota post-infusion. The composition of gut bacteria was associated with the activation status of endogenous CD8+ T cells and responsiveness to CAR-T therapy. More specifically, we identified gut bacteria strains Turicibacter and Parvibactor as critical determinants towards effective CAR-T treatment. Supplementation of these species of gut bacteria during CAR-T cell therapy led to superior antitumor efficacy. Furthermore, both strains facilitated CAR-T therapy-induced activation of endogenous CD8+ T cells, enhancing their capability to express activation-associated surface markers as well as tumor-lysis potency. In summary, our results demonstrate that gut microbiome plays an essential role in endogenous immune activation after CAR-T therapy and provide specific targets for therapeutic interventions.
    DOI:  https://doi.org/10.1158/2326-6066.CIR-25-1230
  13. Front Immunol. 2026 ;17 1714145
      This meta-analysis compared chimeric antigen receptor T-cell (CAR-T) therapy and bispecific antibodies (BsAbs) for relapsed/refractory B-cell non-Hodgkin lymphoma (R/R B-NHL), focusing on efficacy and safety. We analyzed 59 phase I/II trials involving 2,914 patients. CAR-T achieved higher ORR (72% [95% CI 67-77%] vs. 50% [38-62%]) and CR (54% [49-59%] vs. 33% [23-46%]) than BsAbs. However, it was associated with higher rates of grade ≥3 CRS (8% [6-11%] vs. 4% [3-7%]), ICANS (12% [9-16%] vs. 6% [2-18%]), and neurotoxicity (8% [6-10%] vs. 6% [2-13%]). Among CAR-T constructs, dual-targeting products (CD19/20 and CD19/22) showed higher efficacy with more varied toxicity profiles; among BsAbs, CD3×CD20 had a more favorable safety profile relative to CD3×CD19. These results suggest CAR-T may be preferable when deep remission is the priority, whereas BsAbs could be a better fit for frail patients or those seeking outpatient care with lower toxicity risks. Treatment selection should be tailored to patient characteristics, including age, tumor burden, and comorbidities. Together, these results provide a comprehensive, evidence-based framework to guide individualized treatment and sequencing in clinical practice.
    Keywords:  CAR-T therapy; bispecific antibodies; efficacy-safety trade-offs; indirect comparison; relapsed/refractory B-cell non-Hodgkin lymphoma
    DOI:  https://doi.org/10.3389/fimmu.2026.1714145
  14. Front Bioeng Biotechnol. 2026 ;14 1868007
      Advanced Therapy Medicinal Products - cell therapies, gene therapies, and tissue-engineered products - are beginning to deliver on the promise of curative medicine: CAR-T therapies double survival in chemotherapy-refractory lymphomas, gene therapies reverse the natural history of spinal muscular atrophy and hemoglobinopathies, and Pluripotent Stem Cell (PSC)-derived islet transplantation renders type 1 diabetic patients insulin-independent. Yet the trajectory from proof-of-concept to equitable, scalable deployment is consistently impeded not only by unresolved biology but also by engineering, manufacturing, logistical, regulatory, and economic bottlenecks that the bioengineering community has not engaged with at the required scale. In this Perspective, grounded in clinical experience across hematological malignancies, monogenic diseases, and metabolic disorders, we identify five rate-limiting bottlenecks where bioengineering intervention is urgently needed and uniquely tractable: scalable and adaptive biomanufacturing; real-time in-process quality control; precise targeted delivery; biomaterial and scaffold engineering for cellular engraftment and immune protection; and data-driven patient stratification constrained by health equity. We argue that the evolving regulatory landscape in Europe - including the European Biotech Act framework and ICH Quality by Design principles - creates structural incentives for engineering-led solutions, and that economic sustainability requires bioengineering to drive down production costs and enable the off-the-shelf transition. We call on the bioengineering community to engage with ATMP translation not as technical support to clinical medicine, but as a constitutive partner shaping its pace, cost, and equity.
    Keywords:  advanced therapy medicinal products; biomanufacturing; biomaterials; car-t; gene therapy; health equity; iPSC-derived cells; process analytical technology
    DOI:  https://doi.org/10.3389/fbioe.2026.1868007
  15. Clin Pharmacol Ther. 2026 Jul 20.
      Modeling and simulation strategies have evolved from supportive analytical tools to central decision-making engines across drug discovery, development, and regulatory science. By integrating data, models, and stakeholder perspectives, integrator pharmacologists ensure that early discovery decisions translate into robust clinical strategies, meaningful benefit-risk assessments, and ultimately, patient access. This reflection underscores how equity-focused quantitative thinking will pave the path for the next generation of translational science.
    DOI:  https://doi.org/10.1002/cpt.70398
  16. Sci Immunol. 2026 Jul 24. 11(121): eaef4134
      Germline variants influence immune checkpoint inhibitor responses, but their role in engineered immune cell therapies, such as chimeric antigen receptor T cells (CAR T cells), remains unclear. We integrated whole germline sequencing from patients with lymphoma treated with axicabtagene ciloleucel CAR T cell products in the ZUMA-1 and ZUMA-7 clinical trials with detailed biomarker and functional analyses to identify variants influencing clinical toxicity and pharmacokinetics. Putative deleterious variants in STXBP2 (syntaxin binding protein 2) were enriched among patients with toxicity in ZUMA-1, although not confirmed in ZUMA-7. Mechanistically, STXBP2-deficient or variant-expressing T cells triggered increased inflammatory cytokine production and macrophage activation. Conversely, variants in ADAMTSL3, a TGFβ (transforming growth factor-β) signaling regulator, correlated with protection from toxicity across both trials. Furthermore, variants in PTPN22, a negative regulator of T cell receptor signaling, strongly associated with enhanced CAR T cell expansion, a key determinant of efficacy. Together, these findings demonstrate that germline genetics shape the safety and activity of engineered immune cell therapies, affecting future design and patient management.
    DOI:  https://doi.org/10.1126/sciimmunol.aef4134
  17. Eur J Health Econ. 2026 Jul 22.
      Pricing policies may contribute to improving patient access to medicines. Innovative Medicines and Advanced Therapies represent promising treatment options; however, their high costs and limited clinical evidence pose both clinical and financial risks. In many cases, prices do not reflect the actual benefit or degree of innovation, highlighting the need to better understand and refine pricing approaches. The objective of this scoping review is to assess the application of pricing policies for these products worldwide. The methodology followed the JBI Manual for Evidence Synthesis and the PRISMA Extension for Scoping Reviews guidelines. Publications describing pricing policies applied to the definition of prices for Innovative Medicines and Advanced Therapies were included. A comprehensive literature search was conducted. Study selection was performed in two stages by independent reviewers, who also carried out data extraction. Fifty-five publications describing pricing policies for these products across different countries were included. A wide range of policies and methodologies for price determination were identified. The review assessed value-based pricing, external reference pricing, tendering and/or negotiation, internal reference pricing, cost-plus approaches, and initiatives promoting price transparency. Pricing policies play an essential role in regulating the costs of Innovative Medicines and Advanced Therapies. Although such policies may facilitate access to these technologies, challenges such as lack of transparency and heterogeneous methodologies remain. It is crucial that policymakers establish fair and transparent pricing frameworks that balance access, incentives for innovation, and the sustainability of health systems.
    Keywords:  Advanced Therapies; Drug pricing policy; Innovative Medicines; Pricing and reimbursement.
    DOI:  https://doi.org/10.1007/s10198-026-01962-z
  18. Biochim Biophys Acta Rev Cancer. 2026 Jul 18. pii: S0304-419X(26)00109-5. [Epub ahead of print] 189637
      Cell therapy has reshaped the treatment landscape for some hematological malignancies, but its role in urological tumors remains limited and uneven. Early studies in bladder cancer, renal cell carcinoma and prostate cancer suggest that cell therapy can redirect recognition of tumor-associated antigens, enhance cytotoxic effector function and reactivate endogenous antitumor immunity. However, current cell therapies have not yet achieved satisfactory durable responses in most patients. Durable remission depends on more than target recognition: tumor cells must express accessible antigens, and infused cells must enter lesions and maintain their activity within them. More importantly, immune activation must be strong enough to control tumors but sufficiently restrained to avoid systemic toxicity. Therefore, this review evaluates the factors influencing cell therapy from the perspectives of target selection, tumor accessibility, cellular persistence and activation control. It also compares different cell-therapy platforms in light of current clinical evidence and discusses the mechanisms that limit therapeutic efficacy. Finally, it proposes translational priorities and remaining challenges for the further development of cell therapy in urological tumors.
    Keywords:  Adoptive immunotherapy; CAR-T cell therapy; Combination therapy; Prostate cancer; Tumor microenvironment; Urological tumors
    DOI:  https://doi.org/10.1016/j.bbcan.2026.189637
  19. Commun Biol. 2026 Jul 20.
      Chimeric antigen receptor T cell therapy (CAR-T) has demonstrated promising efficacy in hematological malignancies, but translating that success to solid tumors remains challenging. Here, we construct a CAR library comprising approximately 1000 variants targeting prostate-specific membrane antigen by recombining transmembrane (TM), co-stimulatory, and activation domains from Natural Killer (NK) and T cell receptors. Single-cell screening identifies ICOSTM-containing variants with improved T cell activation; NK-derived activation domains, such as DAP10ζ, DAP12ζ, and FcRγζ, further augment the effector capacity. Gene regulatory network analysis reveals that CAR variants with elevated expression of T cell-activation-related transcription factors correlates with enhanced cell function. Overall, our study advances early-stage CAR design by expanding the repertoire of structural components from diverse immune cells, providing a scalable platform for identifying candidates with functional profiles comparable to clinical benchmarks.
    DOI:  https://doi.org/10.1038/s42003-026-10514-3
  20. Drug Resist Updat. 2026 Jul 18. pii: S1368-7646(26)00103-2. [Epub ahead of print]89 101452
      Chimeric antigen receptor (CAR)-based cell therapy holds great promise for the treatment of both hematological malignancies and solid tumors. However, primary and acquired resistance to CAR-based cell therapy remains a key obstacle to achieving effective and durable immunotherapy responses. Unlike small molecules or antibodies, CAR-engineered immune cells offer unique opportunities to design therapeutic agents, thereby enabling the improved products with potential to overcome multiple therapy resistance mechanisms. Therefore, elucidating the mechanisms of resistance to CAR-based cell therapy is crucial for the development of the next-generation CAR-based cell therapy. In this review, we outline the biological rationale of CAR-T, CAR-natural killer (NK), and CAR-macrophages, as well as other emerging CAR-based cell therapies. We focus on the mechanisms of resistance to CAR-based cell therapy, involving structural and functional defects of CAR products, tumor-intrinsic factors, and susceptibility of CAR-engineered cells to the hostile tumor microenvironment. We discuss key strategies to overcome multiple resistance mechanisms, such as targeting multiple antigens, optimizing CAR design and function, modifying the immunosuppressive tumor microenvironment, and developing combination treatment strategies. By systematically dissecting these multifaceted challenges, this review will provide insights for optimizing CAR-based cell therapy to overcome resistance and improve treatment efficacy.
    Keywords:  CAR-NK cells; CAR-T cells; CAR-macrophages; Chimeric antigen receptor; Resistance
    DOI:  https://doi.org/10.1016/j.drup.2026.101452
  21. Cancer Manag Res. 2026 ;18 629588
      CD19- and B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR T-cell) therapies have improved outcomes in relapsed or refractory B-cell lymphoid malignancies and multiple myeloma, but late hematologic complications are increasingly relevant as survivorship expands. This narrative review examines how pre-infusion clonal hematopoiesis (CH), clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of undetermined significance (CCUS), marrow reserve, prior genotoxic exposure, inflammatory stress, and disease-platform context shape the risks of prolonged cytopenia and therapy-related myeloid neoplasms (t-MN) after CAR T-cell therapy. Available evidence suggests that high-risk clonal architecture, particularly TP53-mutated or DNA damage response-associated clones, clonal cytopenia, larger or multiple clones, and heavy prior cytotoxic exposure, is more clinically informative than CHIP positivity alone. By contrast, associations between unstratified CH and prolonged cytopenia remain heterogeneous. CD19 lymphoma and BCMA myeloma settings share clonal-selection biology but differ in marrow ecology, treatment history, baseline cytopenia, inflammatory burden, and surveillance windows. For clinical translation, risk assessment should not rely on universal CHIP screening or binary genomic classification. Instead, clonal-risk models, hematotoxicity-risk models, baseline blood counts, inflammatory markers, prior therapy exposure, and disease-platform context should be integrated to identify patients who may benefit from intensified myeloid surveillance, supportive-care planning, and earlier marrow reassessment while preserving access to CAR T-cell therapy.
    Keywords:  B-cell maturation antigen; CD19; DNA damage response; TP53; chimeric antigen receptor T-cell therapy; clonal cytopenia of undetermined significance; clonal hematopoiesis; clonal hematopoiesis of indeterminate potential; immune effector cell-associated hematotoxicity; therapy-related myeloid neoplasms
    DOI:  https://doi.org/10.2147/CMAR.S629588
  22. Immunol Rev. 2026 Jul;340(1): e70143
      T cells are central to adaptive immunity, recognizing antigenic peptides, called epitopes, via the T cell receptor (TCR). The immense diversity and cross-reactivity of the TCR repertoire makes direct interpretation of antigen specificity from repertoire sequencing challenging. High-throughput sequencing enables large-scale profiling of TCRs but does not directly reveal their target epitopes, requiring computational approaches to bridge this gap. This review outlines two complementary strategies, bottom-up and top-down approaches, to annotate TCR specificity. Bottom-up methods predict TCR-epitope specificity from curated TCR-epitope databases, identifying recurring patterns through distance-based, feature-based, or deep learning models. While effective for well-characterized epitopes, they are limited by biased training data, absence of negative data, and weak generalization to unseen epitopes. Top-down approaches instead infer antigen-driven responses from repertoire-level signals such as sequence similarity, enrichment, and TCR convergence. These methods enable discovery of disease- or exposure-associated TCR signatures without prior epitope knowledge but are sensitive to technical noise and biological confounding. Both approaches are complementary as bottom-up provides mechanistic specificity, while top-down enables discovery in complex datasets. Their integration, alongside multimodal modeling and improved benchmarking, is key to advancing TCR-epitope annotation and understanding adaptive immune responses.
    DOI:  https://doi.org/10.1111/imr.70143
  23. Cancer Res. 2026 Jul 21.
      While chimeric antigen receptor (CAR) T cell therapy has demonstrated significant efficacy in treating hematological malignancies, its application in solid tumors remains challenging. A major limitation of CAR-T cell efficacy in solid tumors is the functional exhaustion of CD8⁺ T cells. Here, we investigated metabolic regulators of CD8⁺ T cell exhaustion, identifying that cystine promotes CD8+ T cell exhaustion. RNA sequencing analysis of an in vitro exhaustion model revealed that SLC7A11 was significantly upregulated in exhausted CD8⁺ T cells. A monoclonal antibody specifically targeting SLC7A11 was subsequently generated, and its binding affinity was rigorously validated. Single-cell RNA sequencing and functional studies demonstrated that inhibition of SLC7A11 promoted the expansion of CD8⁺ stem-like memory T cells and alleviated T cell exhaustion. In vivo, treatment with the anti-SLC7A11 antibody enhanced the antitumor efficacy of CAR-T cells. Mechanistically, SLC7A11 inhibition suppressed cystine uptake, which activated the GCN2-eIF2α-SLC1A5 signaling axis. Upregulation of SLC1A5 increased glutamine uptake to stimulate oxidative phosphorylation and support mitochondrial fitness. Together, these findings demonstrate that cystine restriction alleviates CD8+ T cell exhaustion and enhances the efficacy of CAR-T cell therapy.
    DOI:  https://doi.org/10.1158/0008-5472.CAN-25-4375
  24. Technol Cancer Res Treat. 2026 Jan-Dec;25:25 15330338261473431
      Acute myeloid leukemia (AML) is a heterogeneous group of malignant clonal disorders originating from hematopoietic stem or progenitor cells. Despite significant advances in understanding its pathogenesis and the development of novel therapeutic agents, the overall prognosis for AML patients remains poor. Immunotherapies have demonstrated remarkable success in other hematologic malignancies and are increasingly being explored in AML. However, their clinical application remains challenging, owing to multiple factors such as limited target specificity, high disease heterogeneity, and the immunosuppressive bone marrow microenvironment (BMME). In this review, we provide a comprehensive overview of recent advances in four major immunotherapeutic strategies for AML: adoptive cell therapy, bispecific antibodies, immune checkpoint modulation, and cytokine-based therapies. We further discuss the key biological and clinical challenges that limit their efficacy, including antigen selection, tumor heterogeneity, and microenvironmental immune suppression, along with emerging strategies to overcome these obstacles. With continued progress in both basic and clinical research, immunotherapy holds great potential to achieve greater specificity, improved safety, and more durable responses, ultimately improving outcomes for patients with AML.
    Keywords:  CAR-NK; CAR-T; T cell engagers; acute myeloid leukemia (AML); adoptive cell therapy; chimeric antigen receptor (CAR); cytokines; immune checkpoint modulators; immunotherapy
    DOI:  https://doi.org/10.1177/15330338261473431
  25. Lancet Rheumatol. 2026 Aug;pii: S2665-9913(26)00145-1. [Epub ahead of print]8(8): e664-e673
      Autoantibodies are central to the diagnosis, classification, and stratification of many autoimmune diseases, particularly those characterised by B-cell activation and MHC class II associations. However, a substantial proportion of patients have historically been labelled as seronegative, creating diagnostic uncertainty and suggesting either technical limitations in autoantibody detection or genuinely distinct pathogenic mechanisms. Advances in laboratory assays, encompassing the adoption of recombinant antigens, high-throughput autoantibody profiling, and autoantigen discovery, have progressively reduced the boundaries of seronegativity across several autoimmune diseases. In this Personal View, we discuss how improved autoantibody detection and the identification of novel specificities have reshaped concepts of seronegative disease across different clinically relevant examples of autoimmune diseases. We further examine how autoantibodies inform patient stratification, influence cancer-associated autoimmunity, and even reverse translational immunology implications and pathogenic hints, while highlighting contexts in which genuinely seronegative autoimmunity might still exist.
    DOI:  https://doi.org/10.1016/S2665-9913(26)00145-1
  26. Sci Transl Med. 2026 Jul 22. 18(859): eadt9565
      Clinical efficacy with chimeric antigen receptor (CAR) T cells is currently limited by numerous factors including poor initial product phenotypes and lack of engagement of endogenous immunity. Vasoactive intestinal peptide (VIP) is an immunosuppressive neuropeptide, and the antagonism of its receptor (VIPR) on T cells potentiates T cell activation. We demonstrated that VIP suppresses CAR T cell function and engineered CAR T cells to secrete a short peptide drug that antagonizes VIPR (CAR/VIPRa). Armored CAR/VIPRa T cells maintained a memory phenotype and were metabolically quiescent after manufacturing yet mounted a strong bioenergetic response after antigen stimulation. Moreover, CAR/VIPRa T cells potentiated endogenous antitumor immunity through the recruitment of host T cells. In syngeneic and xenogeneic mouse models of hematological and solid tumors, CAR/VIPRa T cells exhibited greater tumor infiltration and maintained a less exhausted memory phenotype, resulting in superior antitumor efficacy. Together, these data show that VIPRa peptides produced by armored CAR T cells can enhance T cell function and boost endogenous immunity, thereby improving tumor control.
    DOI:  https://doi.org/10.1126/scitranslmed.adt9565
  27. Diagn Microbiol Infect Dis. 2026 Jul 15. pii: S0732-8893(26)00310-X. [Epub ahead of print]116(3): 117560
      Chimeric antigen receptor T-cell (CAR-T) therapies, employing lentiviral vectors, may cause false-positive HIV-1 RNA results due to amplification of vector-derived sequences. We describe a case of a patient with multiple myeloma undergoing CAR-T therapy tested with two dual-target assays testing positive at low copies for HIV-1 RNA. A single-target assay consistently tested negative. HIV serological tests remained non-reactive. This case highlights the importance of assay target design in interpreting HIV RNA results after CAR-T therapy and supports the importance of serological tests and alternative methods to avoid misdiagnosis.
    Keywords:  CAR-T cell therapy; Cross-reactivity; False-positive; HIV-1 RNA; Lentiviral vector
    DOI:  https://doi.org/10.1016/j.diagmicrobio.2026.117560
  28. iScience. 2026 Jul 17. 29(7): 116505
      Single-cell T cell receptor (TCR) sequencing enables high-resolution analysis of TCR diversity and clonal expansion. However, inferring antigen specificity for individual TCRs remains challenging and typically requires costly functional assays. We introduce EpitopeGen, a transformer-based model that generates candidate epitope sequences from TCR sequences, enabling population-level identification of T cell groups with shared predicted antigen specificity. EpitopeGen employs a semi-supervised strategy that searches over 70 billion candidate TCR-epitope pairs and incorporates high-confidence binding predictions as pseudo-labels under biologically inspired quality control. Generated epitopes exhibit high predicted binding probabilities, sequence diversity, realistic biochemical properties, and biophysical stability. In cancer datasets, EpitopeGen identifies clonally expanded tumor-infiltrating CD8+ T cells enriched for tumor-associated antigen recognition and cytotoxic signatures. In patients with COVID-19, it reveals distinct transcriptomic profiles of T cells targeting spike and non-structural proteins across disease severities. EpitopeGen provides a scalable framework for studying disease-associated T cell populations, complementing experimental antigen validation.
    Keywords:  Biological sciences
    DOI:  https://doi.org/10.1016/j.isci.2026.116505
  29. J Transl Med. 2026 Jul 21.
       BACKGROUND: Solid-tumor CAR-T therapy remains limited by antigen heterogeneity, stromal exclusion, abnormal vasculature, immunosuppressive myeloid and fibroblast niches, hypoxia, nutrient competition, mitochondrial stress and inflammatory toxicity. These barriers indicate that solid-tumor CAR-T therapy is not only a receptor-engineering problem but also a systems pharmacology problem requiring rational combinatorial modulation.
    MAIN BODY: This review evaluates whether traditional Chinese medicine (TCM)-derived formulations, botanical compounds and microbiota-derived natural-product metabolites can be developed as mechanism-defined adjuvants for solid-tumor CAR-T therapy. We classify evidence by proximity to CAR-T systems, but also emphasize that evidence ranking must be interpreted within specific use cases. Current evidence remains limited and predominantly preclinical, yet it supports testable intervention concepts involving purified ex vivo metabolic conditioning, in vivo tumor conditioning, concurrent maintenance, toxicity modulation and delivery engineering. We further propose a translational framework linking product identity, exposure window, target annotation, immune-functional potency, CAR-T manufacturing compatibility, pharmacodynamic biomarkers, host-model suitability, lymphodepletion compatibility and safety assessment.
    CONCLUSION: TCM-derived agents should not be developed as empirical supplements for CAR-T therapy. Translation should require defined product identity, target clarity, use-case-specific evidence, exposure window matched to product class, CAR construct, tumor context, manufacturing compatibility, immune-functional potency testing, suitable immune models, lymphodepletion drug-interaction assessment, safety assessment and biomarker-rich early-phase trials with explicit go/no-go criteria.
    Keywords:  CAR-T; Solid tumors; T cell exhaustion; Traditional Chinese medicine; Tumor microenvironment
    DOI:  https://doi.org/10.1186/s12967-026-08672-3
  30. Front Immunol. 2026 ;17 1848770
      Type 1 regulatory T (Tr1) cells are IL-10-producing CD4+ regulatory T cells that play a central role in maintaining peripheral immune tolerance. Prior investigations of autologous Tr1 cell-based therapies have demonstrated clinical promise in graft-versus-host disease (GvHD), but widespread clinical application has been constrained by challenges in scaling cell production. TRX103 is an engineered, allogeneic Tr1 cell therapy manufactured using a fully compliant, current Good Manufacturing Practice-compatible process. TRX103 is generated by pooling engineered CD4+ T cells from three healthy donors that have been transduced with a lentiviral vector encoding human IL-10 and a truncated human nerve growth factor receptor, CD271. In vitro, off-the-shelf TRX103 suppressed effector T cell proliferation and inhibited pro-inflammatory cytokine production by monocytes from both healthy donors and patients with Crohn's disease. In vivo, TRX103 homed to intestinal tissues and prevented disease development in a xenogeneic GvHD model. Phenotypic and functional analyses of TRX103 revealed the acquisition of a distinct cellular identity characterized by reduced expression of activation and immune synapse-associated molecules and minimal allogeneic stimulatory capacity. Together, these findings define a distinct immunomodulatory profile for TRX103 and support its clinical development as a scalable allogeneic cell therapy for immune-mediated diseases. TRX103 is currently being evaluated in a Phase 1/2a study in treatment-refractory Crohn's disease (NCT06721962) and a Phase I study for GvHD prevention in hematopoietic stem cell transplantation recipients (NCT06462365).
    Keywords:  IL-10; Tr1; allogeneic; autoimmunity; cell therapy; regulatory; tolerance
    DOI:  https://doi.org/10.3389/fimmu.2026.1848770
  31. Insights Imaging. 2026 Jul 24. pii: 193. [Epub ahead of print]17(1):
      Artificial intelligence (AI) demonstrates potential throughout the cancer care continuum, with evidence supporting its application in medical imaging for detection, staging, treatment planning, and prognostic evaluation. However, clinical translation is hindered by challenges, data curation and annotation, model interpretability, generalizability, and integration into workflows. To address these barriers and provide guidance, a national multidisciplinary expert panel in China developed this consensus. A modified Delphi approach was employed to achieve expert consensus, involving 81 specialists in radiology, nuclear medicine, oncology, and imaging AI from university hospitals across China. These experts completed a survey containing 30 core statements addressing AI applications in clinical cancer imaging, spanning cancer screening, diagnosis, staging, treatment planning, response assessment, prognostic prediction, data governance, and implementation. Consensus was defined as a mean score ≥ 7 on a 9-point Likert scale, with ≥ 80% of experts scoring ≥ 7. All 30 statements fulfilled these thresholds, with mean scores ranging from 8.06 to 8.58 and the proportion of experts scoring ≥ 7 ranging from 86% to 98%. This expert consensus summarizes key AI application scenarios in cancer imaging and delivers recommendations on data acquisition and annotation, model development and validation, interpretability, multicenter generalizability, privacy-preserving collaboration, clinical workflow integration, and post-deployment monitoring, while contextualizing these statements across major clinical application domains and key implementation challenges in practice. It further identifies priority research directions, including the integration of multimodal and multi-omics data, longitudinal modeling of treatment response, and prospective validation in clinical settings, to support the safe, effective implementation of AI technologies in cancer imaging. KEY POINTS: Question AI translation in oncologic imaging remains constrained by limitations in rigorous validation, actionable interpretability, standardization, governance, and workflow integration. Findings Eighty-one Chinese experts reached consensus on 30 clinically practical statements covering AI applications from early detection to deployment. Critical relevance statement Recommendations highlight expert-supervised labeling, multicenter validation, subgroup evaluation, interpretable outputs, privacy-secured collaboration, integrated workflows, and post-implementation surveillance.
    Keywords:  Artificial intelligence; Consensus; Diagnostic imaging; Machine learning; Neoplasms
    DOI:  https://doi.org/10.1186/s13244-026-02359-5
  32. Cell Rep Methods. 2026 Jul 22. pii: S2667-2375(26)00234-1. [Epub ahead of print] 101533
      Classical type 1 dendritic cells (cDC1s) are crucial to anti-tumor immunity by cross-presenting tumor antigens and priming cytotoxic CD8+ T lymphocytes (CTLs). Licensing via CD4+ T cell help endows cDC1s with enhanced cross-presentation and CTL-priming capacity, making them a promising tool to improve adoptive T cell therapies. However, the scarcity of primary human cDC1s limits their in-depth translational investigation and application. Here, we describe a method to efficiently generate DCs in vitro from CD34+c-KIT+ progenitors in non-mobilized peripheral blood. This DC population is enriched for cDC1-like cells that respond to CD4+ T cell help by upregulation of key molecules involved in antigen cross-presentation and T cell costimulation. Upon CD4+ T cell-mediated licensing, the progenitor-derived DC promotes tumor-specific CTL priming and facilitates detection of rare tumor antigen-specific CD8+ T cells in blood and tumor tissues. This DC culture platform incorporating CD4+ T cell help provides a scalable system for immunomonitoring and optimizing adoptive T cell therapies in cancer.
    Keywords:  CP: cancer biology; CP: immunology; adoptive cell therapy; blood progenitor; cDC1-licensing; cDC1-like cell generation; tumor antigen-specific CTL
    DOI:  https://doi.org/10.1016/j.crmeth.2026.101533
  33. Curr Opin Immunol. 2026 Jul 20. pii: S0952-7915(26)00095-6. [Epub ahead of print]102 102818
    Paediatric Rheumatology INternational Trials Organisation (PRINTO) and the Pediatric Rheumatology Associated Group of Milan and Lombardy Area (PRAGMA)
      The development of clinical trials is limited by high costs and methodological complexities. In this context, artificial intelligence (AI) is emerging as a key instrument for their optimization. In the early phases of study design and recruiting, generative AI systems may help refine eligibility criteria and boost enrollment; in parallel, the integration of digital biomarkers and patient-reported outcomes may allow continuous remote monitoring and improved safety data collection. Moreover, machine learning models may be applied to effectively analyze longitudinal multimodal trial data. However, AI implementation in real-world settings must overcome significant challenges; regulatory authorities are updating guidance, and a successful integration of AI-based interventions will depend on the rigorous application of quality standards while preserving the central role of medical judgment. In this review, we provide a comprehensive overview of the clinical applications, ethical considerations, and regulatory aspects of implementing AI in clinical trials in adult and pediatric rheumatology.
    DOI:  https://doi.org/10.1016/j.coi.2026.102818
  34. Hell J Nucl Med. 2026 Jan-Apr;29 Suppl:29 Suppl 16-28
      Nuclear medicine has progressed from an exploratory discipline, historically constrained by limited spatial resolution and qualitative interpretation, into a rigorously quantitative clinical specialty. This evolution represents a systematic conversion of uncertainty into actionable information. Uncertainty that was once implicit and observer-dependent is increasingly measured, modelled, and managed across the full imaging-therapy continuum. Early tracer work established the foundational diagnostic logic of assessing function before structure. Subsequent instrumentation advances, culminating in the contemporary deployment of long axial field-of-view total-body positron emission tomography (PET) and digital cadmium-zinc-telluride detectors, have compressed spatial ambiguity and enabled true dynamic, multi-organ kinetic modelling. Hybrid imaging further reduced uncertainty by coupling functional signals to anatomical context, while artificial intelligence has emerged as a transformative force, enabling synthetic attenuation correction, automated total tumour volume segmentation, and the deployment of 3D vision-language foundation models for multimodal analysis. Parallel progress in radiochemistry and target biology has shifted tracer development toward highly specific receptor and antigen ligands. This momentum catalysed the theranostics revolution, where diagnostic imaging serves as an explicit, quantitative gatekeeper for radiopharmaceutical therapy. As the field transitions into the "Alpha-Era"-characterized by the clinical maturation of targeted alpha therapies-dosimetry and radiobiology have become paramount. To harness this complexity, the discipline is adopting Theranostics Digital Twins, advanced computational frameworks that integrate physiologically-based radiopharmacokinetic models, radiobiological optimizers, and patient-specific multi-omics to predict dose-response and mitigate toxicity. Though modern nuclear medicine has not eliminated biological uncertainty, it has formalized its quantification, establishing a highly personalized and augmented therapeutic paradigm capable of overriding sub-clonal tumour resistance and redefining systemic oncology.
  35. J Clin Pharmacol. 2026 Jul;66(7): e70242
      Pediatric oncology drug development remains uniquely challenging due to the rarity and biological heterogeneity of childhood cancers, ethical considerations in trial conduct, and the limited feasibility of large, randomized studies. Despite these barriers, recent years have seen a notable acceleration in the approval of oncology therapies for pediatric populations, driven by advances in molecularly targeted treatments, evolving regulatory requirements, and innovation in trial design. Reducing nonclinical data requirements and increasing the adaptation of model‑informed drug development approaches are also contributing to advances in pediatric oncology treatment by supporting dose selection, optimizing study design, and reducing unnecessary patient burden. In this review, recent regulatory requirements from the United States, the EU, and other key regions on pediatric oncology drug development are discussed. Thirty-three drugs with oncology indications in pediatric populations approved by the US FDA between 2018 and 2025 are reviewed. These approvals provide examples of how nonclinical and clinical data were generated with a focus on strategies for dose-finding and justification. Common challenges and considerations related to clinical operations and formulation development in pediatric populations and the emerging use of real-world data, external controls, and artificial intelligence/machine learning are also discussed.
    Keywords:  clinical pharmacology; clinical trial design; model‐informed drug development; oncology; pediatric; real‐world evidence
    DOI:  https://doi.org/10.1002/jcph.70242
  36. Signal Transduct Target Ther. 2026 Jul 23. pii: 289. [Epub ahead of print]11(1):
      In situ cancer vaccination, also termed intratumoral immunotherapy, transforms the tumor microenvironment into an endogenous vaccine platform by leveraging the tumor itself as a source of antigens. Unlike conventional tumor-associated antigen (TAA) or personalized neoantigen vaccines that require predefined targets and complex manufacturing, in situ cancer vaccination presents the tumor's full antigenic repertoire, including TAAs, neoantigens, post-translationally modified epitopes, cryptic peptides, and viral antigens within their native context. This broad antigen exposure elicits robust polyclonal cytotoxic T-cell responses, facilitates epitope spreading, and reduces immune escape driven by tumor heterogeneity. The therapeutic efficacy of this approach arises from the coordinated activation of multiple immune mechanisms. Programmed cell death pathways, including immunogenic apoptosis, pyroptosis, necroptosis, and ferroptosis, release tumor antigens and danger-associated molecular patterns (DAMPs) that promote dendritic-cell activation, efficient cross-presentation, and the priming of durable effector and memory T cells. The incorporation of potent adjuvants and advanced delivery platforms enhances innate-adaptive crosstalk and helps remodel the immunosuppressive tumor microenvironment. Despite these advantages, clinical translation is limited by inconsistent induction of immunogenic cell death, suboptimal intratumoral retention of therapeutics, and barriers to T-cell infiltration. Recent advances in nanomedicine-enabled delivery systems, microenvironmental modulation, and combinatorial strategies, particularly with immune checkpoint blockade, are overcoming these challenges. Collectively, these innovations position in situ cancer vaccination as a patient-tailored, broadly applicable immunotherapy capable of eliciting durable and systemic antitumor immunity.
    DOI:  https://doi.org/10.1038/s41392-026-02821-2
  37. Orphanet J Rare Dis. 2026 Jul 21.
      Rare eye diseases bring unique challenges in clinical research and patient care due to their heterogeneity, low prevalence, and dispersed expertise. To address these challenges, an integrated multilevel data strategy has been developed in France and Europe, enabling structured, interoperable data collection and reuse across national and transnational initiatives. In this paper, we present a methodological framework using the metaphor of a spaceship to illustrate the vertical articulation of this ecosystem, from national infrastructures to European platforms. At the base of the spaceship lies BaMaRa, France's national registry for rare diseases, which ensures the systematic collection of core clinical data at the point of care. The next stage is FREDD, a disease-specific data warehouse dedicated to rare eye conditions, developed by the SENSGENE network thanks to the France 2030 RaReTiA project. FREDD integrates granular phenotypic and genotypic data, allowing for in-depth research and cohort building. FREDD is fully interoperable with BaMaRa, ensuring data consistency and minimizing redundancies. The third level of the spaceship is REDgistry, the European registry for rare eye diseases coordinated by ERN-EYE. REDgistry allows for cross-border data harmonization and aligns with FAIR principles to facilitate data sharing and secondary use in international research. At the top of the structure is the European Health Data Space, a future platform enabling secure and standardized access to health data for research and policy-making at the EU level. At the core of this architecture remains the patient, whose data is the very foundation of the system. Although not always actively involved in data collection, the patient remains central to the purpose and structure of each data layer. Building and sustaining such a complex infrastructure requires the coordination of a wide range of stakeholders, including clinicians, research networks, data stewards, hospital IT departments, national authorities, and European institutions. The success of this multilevel model depends on shared standards, transparent governance, and sustained collaboration across all actors. Together, they form the propulsion system of the spaceship, enabling the structured reuse of high-quality data to accelerate research and improve care in the field of rare eye diseases.
    Keywords:  BNDMR; BaMaRa; Data governance; ERN-EYE; Health care data secondary use; Health data warehouse; Interoperability; Rare eye diseases; SENSGENE
    DOI:  https://doi.org/10.1186/s13023-026-04505-0
  38. Mol Ther. 2026 Jul 20. pii: S1525-0016(26)00607-6. [Epub ahead of print]
      CAR T cell therapy to treat solid tumors has seen limited success, partly due to tumor heterogeneity and antigen escape. These barriers remain major challenges, as heterogeneous tumors often consist of diverse populations of cancer cells, which can downregulate or lose the targeted antigens following the treatment, thereby evading CAR T cell recognition and killing. To address this challenge, we engineered CAR T cells to secrete bispecific T cell engagers (BTCEs) targeting EpCAM. EpCAM is a tumor-associated antigen widely expressed in epithelial derived tumors but often considered "undruggable" by conventional targeted therapies due to its expression in normal epithelial cells. Secretion of the anti-EpCAM BTCEs by CAR T cells localizes BTCEs to the tumor site, preventing antigen escape while limiting systemic toxicity. This tactic successfully uses CAR T cells as carriers to restrict BTCE activity within the tumor microenvironment. Here, we show that in the preclinical models, GPC3, DLL3, and HER2-targeted CARs that secrete anti-EpCAM BTCEs can completely eradicate heterogeneous tumors of epithelial origins and stop antigen escape. Our results highlight the versatility of this technology across various epithelia originated carcinomas and imply that this strategy has significant translational potential to enhance solid tumor immunotherapy.
    DOI:  https://doi.org/10.1016/j.ymthe.2026.07.041
  39. Int J Hematol. 2026 Jul 23.
      Immune effector cell-associated neurotoxicity syndrome (ICANS) is a serious early adverse event of chimeric antigen receptor T (CAR-T) cell therapy. ICANS typically occurs concurrently with or follows cytokine release syndrome (CRS), suggesting CRS can be considered the primary risk factor for ICANS onset. Therefore, CRS characteristics in an individual patient may predict their risk for subsequently developing ICANS. We analyzed 154 patients with B cell lymphoma treated with commercial CAR-T products between 2020 and 2024; 38 patients (24.7%) developed ICANS after CRS. The cohort was split into a derivation set and a validation set. In the derivation cohort, univariate analysis identified two CRS-related factors strongly associated with ICANS: CRS onset within 24h and grade 2-4 CRS by day 3. Using these two variables, we created a simple predictive model that stratified patients into high-, intermediate-, and low-risk groups, with ICANS incidences of 47.4%, 31.0%, and 8.2%, respectively. The validation cohort confirmed this trend. These findings suggest that early CRS characteristics provide a practical, clinically applicable method for estimating ICANS risk and may support timely management decisions in CAR-T therapy.
    Keywords:  B-cell NHL; CAR-T; ICANS
    DOI:  https://doi.org/10.1007/s12185-026-04257-4
  40. Transfus Clin Biol. 2026 Jul 18. pii: S1246-7820(26)00119-9. [Epub ahead of print]
       BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy is frequently complicated by prolonged cytopenias requiring transfusion. Comparative real-world data on transfusion burden across commercial CAR-T products and post-therapy alloimmunization risk remain limited.
    METHODS: We retrospectively reviewed 102 patients treated with idecabtagene vicleucel (Abecma), ciltacabtagene autoleucel (Carvykti), lisocabtagene maraleucel (Breyanzi), axicabtagene ciloleucel (Yescarta), or brexucabtagene autoleucel (Tecartus) at a single center. Red blood cell (RBC) and platelet transfusions were quantified over 0-30, 30-90, and 90-180 days post-infusion. Kruskal-Wallis tests and negative binomial regression with disease-stratified interpretation were used to estimate incidence rate ratios with 95% confidence intervals. Alloimmunization was assessed through routine, clinically driven antibody screening.
    RESULTS: Adjusted exploratory models detected no product-specific differences in RBC support. Platelet transfusion distributions varied by product and disease group, but these findings were based on small absolute counts and were driven by a minority of high-need patients; therefore, they should be interpreted as hypothesis-generating rather than definitive product-level differences. No new RBC alloantibodies were detected through routine clinical antibody screening.
    CONCLUSION: Transfusion needs after CAR-T therapy were concentrated in the first 30 days and were modest overall, with most patients transfusion-free thereafter. This real-world descriptive analysis helps fill a current gap in understanding transfusion-support patterns across commercial CAR-T products and disease groups. Apparent product- and disease-related differences were driven by a minority of high-need patients and should be considered hypothesis-generating. No new RBC alloantibodies were detected through routine clinical screening, although standardized antibody surveillance was not performed.
    Keywords:  CAR T-cell therapy; blood component transfusion; hematologic toxicity; platelet transfusion; red blood cell transfusion; red cell alloimmunization
    DOI:  https://doi.org/10.1016/j.tracli.2026.07.008
  41. Eur J Health Econ. 2026 Jul 21.
       OBJECTIVES: This study provides a comprehensive overview of the Italian framework for the appraisal of drug innovativeness, covering all 294 appraisals conducted by AIFA between 2017 and June 2025. It aims to describe the evolution and application of the 2017 criteria, explore the determinants of innovativeness recognition, and discuss the implications of the 2025 revision for value assessment and market access.
    METHODS: All AIFA innovativeness reports available up to June 2025 were systematically reviewed and coded across the three appraisal domains - therapeutic need, added therapeutic value, and quality of evidence - together with contextual and regulatory variables (orphan designation, study design, EMA approval type, accelerated assessment, and PRIME designation). Descriptive and multinomial regression analysis were performed to identify predictors of appraisal outcomes and to explore associations with European and national timelines.
    RESULTS: Among 294 appraisals, 27% were fully innovative, 29% conditionally innovative, and 44% non-innovative. ATV and quality of evidence were the strongest determinants, while therapeutic need played a secondary role. Orphan designation, pediatric/mixed populations, and the availability of RCT-based evidence increased the likelihood of a positive outcome. Medicines with EMA accelerated assessment were more often granted full innovativeness but did not achieve shorter national reimbursement timelines (median 432 days). Fully innovative medicines followed shorter EMA pathways (median 330 vs. 448 days), though not necessarily implying faster national access.
    CONCLUSIONS: AIFA's framework proved internal coherence, with ATV as the main driver. The 2025 criteria may enhance methodological rigor but reduce flexibility, requiring continuous monitoring to ensure timely and equitable access.
    Keywords:  AIFA (italian medicines agency); Added therapeutic value; Drug innovativeness; Health technology assessment (HTA); Market access; Regulatory timelines
    DOI:  https://doi.org/10.1007/s10198-026-01956-x
  42. Front Digit Health. 2026 ;8 1720615
      Healthcare technologies are increasingly reshaping how diseases are detected, monitored, treated, and managed across healthcare systems. Advances in artificial intelligence (AI), digital health, remote monitoring, advanced medical devices, and data-driven clinical infrastructures are creating important opportunities to improve prevention, diagnostic accuracy, personalisation of care, workflow efficiency, and long-term healthcare sustainability within the framework of predictive, preventive, personalized, and participatory medicine (4P Medicine). However, despite growing technological sophistication and investment, many innovations fail to achieve scalable and sustainable implementation in real-world clinical environments. This narrative review critically examines the systemic factors that condition the successful translation of healthcare technologies into routine clinical practice, with particular emphasis on the European and Spanish contexts. Rather than focusing exclusively on technological performance, the review analyses the broader regulatory, organisational, financial, ethical, and governance challenges that shape implementation. Key areas discussed include technology transfer, regulatory frameworks, health data governance, and the organisational challenges associated with implementing AI-driven healthcare technologies. The central argument of this review is that the real-world impact of healthcare innovation depends less on technological capability itself than on the capacity of healthcare systems to support validation, regulation, implementation, workforce adaptation, interoperability, and long-term governance. Consequently, the principal challenge for contemporary healthcare systems is no longer simply how to develop new technologies, but how to integrate them safely, equitably, and sustainably into routine clinical practice.
    Keywords:  healthcare; innovation; policies; sustainability; technology
    DOI:  https://doi.org/10.3389/fdgth.2026.1720615
  43. Cell Transplant. 2026 Jan-Dec;35:35 9636897261471702
      Chronic graft-versus-host disease (cGVHD) remains the leading cause of late non-relapse mortality and long-term disability after allogeneic hematopoietic cell transplantation (allo-HCT), affecting 30-70% of long-term survivors. Despite its substantial morbidity and the toxicities associated with prolonged corticosteroid use, therapeutic advances have accelerated considerably. This review synthesizes current mechanistic insights and clinical evidence within the framework of the well-established three-phase pathogenesis model of cGVHD. Phase 1 (early inflammation) involves tissue injury and innate immune activation; Phase 2 (months 2-12) is characterized by impaired central and peripheral tolerance with aberrant B- and T-cell responses; Phase 3 (>1 year) features macrophage-driven fibrosis and end-organ damage. Recognizing that these phases are conceptual and frequently overlap in clinical practice, we explore the alignment of contemporary biomarkers with each phase-ST2/CXCL9 (Phase 1), BAFF/autoantibodies (Phase 2), and MMP3/TGF-β (Phase 3)-and discuss how FDA-approved agents (ibrutinib, ruxolitinib, belumosudil, axatilimab) may target phase-specific pathways. A conceptual, risk-stratified treatment algorithm is proposed to link pathobiology to clinical decision-making, with the important caveat that biomarker-guided selection remains investigational and currently complements, rather than replaces, comprehensive clinical assessment. Notably, the adoption of prophylaxis and upfront strategies to prevent cGVHD has substantially reduced cGVHD incidence in modern cohorts.
    Keywords:  allogeneic hematopoietic-cell transplantation; chronic graft-versus-host disease; therapeutic targets
    DOI:  https://doi.org/10.1177/09636897261471702
  44. Front Immunol. 2026 ;17 1894189
      Cancer immunotherapy depends on effective antigen presentation and T cell activation. Antigen-presenting cells (APCs), especially dendritic cells (DCs), play a central role in this process by capturing tumor antigens, processing them, and presenting antigenic peptides to T cells through major histocompatibility complex molecules. However, APC function is often impaired within the tumor microenvironment. Reduced antigen presentation, weak co-stimulatory signaling, suppressive cytokines, metabolic stress, and inhibition by myeloid-derived suppressor cells and regulatory T cells all limit effective antitumor immunity. These defects contribute to immune escape and reduce the efficacy of current immunotherapies. In this mini review, we summarize the key roles of APCs in antitumor immune responses and discuss major APC-based therapeutic strategies, including dendritic cell vaccines, nanoparticle-based antigen delivery, mRNA vaccine platforms, DC-targeted delivery systems, and oncolytic virus-based combinations. We also highlight functional reprogramming approaches that aim to restore APC activity through innate immune activation, blockade of immunosuppressive cytokines, and metabolic regulation. Although these strategies have shown strong potential, their clinical translation remains limited by tumor antigen heterogeneity, complex manufacturing, poor immune infiltration, and persistent immunosuppression in the tumor microenvironment. Future APC-based immunotherapy should move beyond single antigen presentation enhancement and focus on integrated immune remodeling. Rational combinations with immune checkpoint blockade, innate immune agonists, radiotherapy, chemotherapy, and biomarker-guided patient selection may help generate stronger and more durable antitumor responses.
    Keywords:  STING pathway; antigen-presenting cells; cancer immunotherapy; combination immunotherapy; dendritic cells; immunometabolic reprogramming; mRNA vaccine; oncolytic virus
    DOI:  https://doi.org/10.3389/fimmu.2026.1894189
  45. Front Immunol. 2026 ;17 1790344
      Immune checkpoint blockade has transformed cancer therapy by demonstrating that durable tumour control can be achieved through immune modulation rather than direct cytotoxicity. However, primary resistance remains the dominant clinical outcome across solid tumours, reflecting a fundamental limitation of checkpoint inhibitors: they do not initiate antitumour immunity, but amplify immune responses that are already underway. Here, we advance immune readiness as a unifying framework to explain primary resistance to immune checkpoint inhibitors. Immune readiness is defined as a dynamic and programmable host-tumour state characterised by competent innate sensing, type I interferon-driven myeloid activation, dendritic-cell licensing, coordinated antigen presentation, productive lymphocyte priming, and permissive inflammatory trafficking into tumour tissue. In the absence of these upstream processes, checkpoint blockade is biologically inconsequential, regardless of tumour antigenicity or checkpoint expression. Within this framework, therapeutic vaccination is positioned as a flexible immune-conditioning strategy that can induce, amplify, or synchronise immune readiness rather than as a direct cytotoxic modality or rigidly antecedent intervention. Tumour-directed, immune-modulatory, and tumour-agnostic vaccines may construct the immunological substrate required for checkpoint efficacy when integrated before, during, or in close temporal coordination with checkpoint blockade. Engineering immune readiness through vaccination-enabled immunotherapy offers a coherent strategy to overcome primary resistance and expand the therapeutic reach of cancer immunotherapy.
    Keywords:  cancer therapy; immune checkpoint blockade; immune readiness; primary resistance; therapeutic vaccination
    DOI:  https://doi.org/10.3389/fimmu.2026.1790344
  46. Clin Transl Immunology. 2026 ;15(7): e70116
       Objectives: Immune reconstitution following chimeric antigen receptor (CAR)-T cell therapy remains a critical clinical challenge, and the determinants of natural killer (NK)-cell recovery are not fully understood.
    Methods: We longitudinally monitored natural killer (NK)-cell recovery in 64 patients during the first year after CD19-directed CAR-T cell therapy, analysing NK-cell counts and surface receptor expression. Associations between cytokine release syndrome (CRS), cytokine profiles, and NK-cell numerical reconstitution were evaluated, and mechanistic insights were explored using in vitro NK-cell assays.
    Results: NK-cell numerical and phenotypic recovery was impaired within the first month after CAR-T cell infusion. Notably, NK-cell numerical recovery was significantly delayed in patients who developed CRS. A reduced NK-to-T cell ratio at one-month post-infusion was associated with a markedly increased risk of viral infection (hazard ratio = 4.512). Elevated interleukin (IL)-10 levels during CRS were inversely associated with NK-cell recovery. Patients with high IL-10 levels exhibited delayed NK-cell reconstitution, which was independently validated in two external cohorts. Mechanistically, in vitro exposure of NK cells to IL-10 promoted caspase-3 activation, increased apoptosis, and enhanced reactive oxygen species accumulation and lipid peroxidation. Rescue experiments using ferrostatin-1 and Z-VAD-FMK further supported the involvement of IL-10 in apoptosis and ferroptosis.
    Conclusion: These findings highlight a previously underappreciated role of IL-10 in shaping NK-cell reconstitution post-CAR-T cell therapy, particularly in the setting of CRS. Patients with CRS accompanied by elevated IL-10 levels may benefit from anti-inflammatory interventions or therapeutic strategies aimed at promoting NK-cell recovery.
    Keywords:  NK‐cell recovery; apoptosis; chimeric antigen receptor T‐cell therapy; cytokine release syndrome; ferroptosis; interleukin‐10
    DOI:  https://doi.org/10.1002/cti2.70116